**Abstracts**

**2022-RA-1546-ESGO**

**POTENTIAL APPROACH TO OVERCOME PRIMARY LEIOMYOSARCOMA OF FEMALE WITH RECURRENCE ENDOMETRIAL CARCINOMA**

Sebastian Schott, 1Sara Alavi, 1Lukas Chinczeewski, 1Chiara Flethe, 2Elena Baicu, 1Klaus Pietzner, 1Radoslav Cvejic, 1Wolfgang Daniel Schmitt, 1Julid Sehouli, 1Frauenklinik, Charité, Berlin, Germany; 2Charité, Berlin, Germany; 3Institut für Pathologie, Charité, Berlin, Germany

10.1136/ijgc-2022-ESGO.339

**Introduction/Background** The adjuvant treatment of endometrial carcinoma is constantly evolving. The introduction of checkpoint inhibitors in the therapy of recurrent endometrial carcinoma marked a milestone in the clinical outcome. Nevertheless, there is a need to develop possible treatment strategies to overcome a checkpoint inhibitor resistance.

**Methodology**

**Results** We present a case of 79-year-old patient diagnosed with endometrioid endometrial carcinoma in 2010. Laparoscopically assisted vaginal hysterectomy with salpingo-oophorectomy and systematic pelvic and paraaortic lymphadenectomy was performed, and the carcinoma was classified as pT1b G2 R0 L0 V0 FIGO IB. Two years later a vaginal stump recurrence was resected, macroscopically tumor free. Five years after initial diagnosis, the patient presented with pulmonary metastasis. Chemotherapy was started with weekly paclitaxel and carboplatin for twelve cycles. Moreover, the patient underwent combined radio-chemotherapy in June 2016. Six months later the patient was first diagnosed with cerebral metastasis, stereotactic radiation was followed by MPA for 10 months. In November 2017 due to the third local recurrence, a laparotomy with resection of the tumor from the pelvic wall and the iliac vessels was performed and hysterectomy was initiated. In 2020 a pathological examination confirmed an EEC – p53 wt, hormone receptor positive and a microsatellite instability with loss of PMS2 and MLH1. In 2020 the patient presented infiltration of the bladder. Immunotherapy with checkpoint inhibitor was initiated but the tumor showed image morphological progression after 9 months. Due to the progression the addition of lenvatinib was recommended. Under this combination therapy the tumor showed a stable disease ever since in total of 21 months and with some lesions to partial response.

**Conclusion** The combination of checkpoint inhibitor and a tyrosine kinase inhibitor is a potential approach to overcome checkpoint inhibitor resistance. Further clinical trials are warranted.

**2022-RA-1550-ESGO**

**THERAPEUTIC EFFECT OF T-CELL-DERIVED NANOVESICLES IN ENDOMETRIAL CANCER**

Young Shin Chung. Kyung Hee University Hospital at Gangdong, Seoul, Korea, Republic of Korea

10.1136/ijgc-2022-ESGO.341

**Introduction/Background** T cell therapy, including adoptive T cell transfer and immune checkpoint blockades, is a remarkable advance in cancer immunotherapy, but its therapeutic effect on solid tumors is limited. A main cause of the low efficacy is T-cell exhaustion by immunosuppressive mechanisms of solid tumors, which are mainly mediated by PD-L1. To address some of the challenges faced by the current cancer immunotherapy, we developed human T-cell-derived nanovesicles using a perfusable vascular network hydrogel with culturing patient tissues.

**Methodology** Human T-cell-derived nanovesicles produced by the serial extrusion of human cytotoxic T cells through membranes with nanosized pores that inhibit T-cell exhaustion and exhibit antitumoral activity maintained in the immunosuppressive tumor microenvironment are presented.

**Results** Similar to cytotoxic T cells, human T-cell-derived nanovesicles can be targeted at tumors via T-cell-membrane-originated proteins and kill cancer cells by releasing anticancer molecules such as granzyme B. Unlike cytotoxic T cells, human T-cell-derived nanovesicles are resistant to immunosuppressive molecules (e.g. PD-L1) of cancer cells by scavenging PD-L1, thereby preventing cytotoxic-T-cell exhaustion. Human T-cell-derived nanovesicles successfully inhibit tumor growth in a 3D human endometrial cancer chip using a perfusable vascular network hydrogel with culturing the same patients' tissues. Indeed, human T-cell-derived nanovesicles exhibit higher therapeutic efficacy than an immune checkpoint blockade in endometrial treatment.

**Conclusion** We propose to present these aspects of the human T-cell-derived nanovesicle to eventually improve the current cancer immunotherapy strategy and overcome the tumor’s immunosuppressive mechanisms.